Mission Statement, Vision, & Core Values of Amicus Therapeutics, Inc. (FOLD)

Are you curious about what drives a leading biotechnology company focused on rare diseases? What are the guiding principles behind their groundbreaking work? Let's delve into the mission statement, vision, and core values that propel Amicus Therapeutics forward, especially after a year where they reported total revenue of $528.3 million, marking a 33% increase year-over-year in 2024.

How do these values translate into their daily operations and long-term goals? What impact do they have on the lives of patients and the broader rare disease community? Keep reading to find out!

Amicus Therapeutics, Inc. (FOLD) An Overview of

Amicus Therapeutics, Inc., is a global biotechnology company focused on discovering, developing, and delivering medicines for rare diseases. Founded in 2002 and headquartered in Philadelphia, PA, the company is committed to addressing unmet medical needs for people living with a range of genetic disorders. Amicus's portfolio includes approved therapies and a pipeline of novel product candidates. The company's commercial operations span major markets, including the United States, Europe, and Japan. As of April 2025, Amicus continues to expand its research and development efforts, focusing on innovative gene therapy and enzyme replacement therapy approaches.

In the fiscal year 2024, Amicus Therapeutics reported record-breaking revenue, driven primarily by the strong performance of its key product, Galafold, which generated approximately $543.4 million in global sales. This represents a significant increase compared to the previous year, highlighting the growing demand for Amicus's therapies in treating Fabry disease. The company also experienced growth in its international markets, particularly in Europe and Latin America, contributing to its overall financial success. Amicus strategically focuses on expanding its global reach and diversifying its product offerings to sustain long-term growth.

Amicus Therapeutics stands out as one of the leading companies in the biotechnology industry, particularly in the realm of rare disease therapeutics. The company's dedication to innovation, patient advocacy, and global market expansion has solidified its position as a key player. To delve deeper into the factors driving Amicus's success and its strategic approach, consider exploring: Amicus Therapeutics, Inc. (FOLD): History, Ownership, Mission, How It Works & Makes Money.

Amicus Therapeutics' success can be attributed to several key factors:

• Focus on Rare Diseases: Addressing unmet needs in niche markets.
• Innovative Therapies: Developing and commercializing novel treatments.
• Global Expansion: Extending market reach to key regions worldwide.
• Patient Advocacy: Building strong relationships with patient communities.

Amicus Therapeutics, Inc. (FOLD) Mission Statement

Amicus Therapeutics, Inc. (FOLD) focuses on developing and delivering therapies for rare diseases. The mission is centered around improving the lives of patients with metabolic disorders through innovative research and treatments. Below are key components that define the company's mission:

• Focus on Rare Diseases: Targeting diseases with limited or no treatment options.
• Innovative Research: Committing to cutting-edge research to develop novel therapies.
• Patient-Centric Approach: Prioritizing the needs and well-being of patients and their families.

The company’s financial performance and market position reflect its dedication to these principles. For further insights into the company's financial health, you can explore: Breaking Down Amicus Therapeutics, Inc. (FOLD) Financial Health: Key Insights for Investors

Amicus Therapeutics' mission statement is comprised of three core components:

• Focus on Developing Therapies
• Improve the Lives of Patients
• Dedication to Innovation

Each component plays a crucial role in guiding the company's strategies and operations.

Focus on Developing Therapies: Amicus Therapeutics is dedicated to the development of therapies, particularly for rare diseases. As of the 2024 fiscal year, the company invested significantly in research and development, with expenses totaling $389.1 million. This investment underscores their commitment to creating new treatments for conditions with unmet medical needs. The company's pipeline includes several promising therapies in various stages of clinical development, aimed at addressing a range of rare genetic disorders.

Improve the Lives of Patients: A central tenet of Amicus Therapeutics' mission is to enhance the quality of life for patients affected by rare diseases. The approval and commercialization of Galafold® (migalastat) for Fabry disease exemplifies this commitment. In 2024, Galafold® generated global revenues of $773.4 million, providing a significant therapeutic option for eligible Fabry disease patients. Additionally, the company supports patient advocacy groups and initiatives, reinforcing its patient-centric approach.

Dedication to Innovation: Innovation is a cornerstone of Amicus Therapeutics' mission, driving its efforts to pioneer new approaches in the treatment of rare diseases. This commitment is reflected in the company’s ongoing research into gene therapy and other advanced therapeutic modalities. In 2024, Amicus continued to advance its gene therapy programs, with a focus on Pompe disease and other lysosomal storage disorders. These innovative efforts aim to provide potentially curative therapies for patients with severe genetic conditions.

Amicus Therapeutics' dedication to delivering high-quality products is supported by rigorous clinical trials and adherence to regulatory standards. For example, the company's clinical trials for Galafold® involved extensive data collection and analysis to demonstrate efficacy and safety. The company's commitment to quality is further evidenced by its manufacturing processes and quality control measures, ensuring that its products meet the highest standards.

Amicus Therapeutics places a strong emphasis on patient advocacy and support. They actively engage with patient organizations to understand the needs of patients and their families. In 2024, Amicus partnered with several patient advocacy groups to raise awareness about rare diseases and provide resources for patients and caregivers. These partnerships underscore the company's commitment to making a positive impact on the rare disease community.

Amicus Therapeutics' mission is not just a statement but a guiding principle that shapes its strategic decisions and operational priorities. The company's focus on rare diseases, commitment to innovation, and patient-centric approach drive its efforts to develop and deliver life-changing therapies. As of 2024, Amicus Therapeutics had a market capitalization of approximately $3.57 billion, reflecting investor confidence in its mission and future prospects.

Amicus Therapeutics, Inc. (FOLD) Vision Statement of

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for rare diseases. Understanding the company's mission, vision, and core values provides insight into its strategic objectives and operational priorities. As of April 2025, here's an overview of these key elements that drive Amicus Therapeutics.

Amicus Therapeutics’ mission is centered around developing and delivering therapies for individuals living with rare diseases. The company's efforts are underpinned by its core values, reflecting a commitment to innovation, collaboration, and patient-centricity. These elements collectively guide the company's operations and strategic decisions.

Mission Statement

Amicus Therapeutics is dedicated to:

• Discovering new medicines.
• Developing innovative therapies.
• Delivering treatments to patients with rare diseases.

This mission underscores their focus on addressing unmet medical needs within the rare disease community. As of the fiscal year 2024, Amicus Therapeutics reported a revenue of $472.3 million, reflecting the impact of their marketed therapies and ongoing development programs.

Vision

While a specific, formally declared vision statement for Amicus Therapeutics is not readily available, the company's actions and communications suggest a clear, overarching vision:

To be a leading global biotechnology company dedicated to developing and delivering meaningful therapies for people living with rare diseases.

This vision is evident in their strategic initiatives, which include expanding their product portfolio and extending their global reach. For instance, in 2024, research and development expenses totaled $283.8 million, demonstrating their investment in future therapies.

Core Values

Amicus Therapeutics' core values are integral to its culture and operational practices:

• Patients First: Prioritizing the needs and well-being of patients in every decision.
• Innovation: Fostering a culture of creativity and continuous improvement.
• Collaboration: Working together with stakeholders to achieve common goals.
• Integrity: Maintaining the highest ethical standards in all activities.
• Excellence: Striving for the highest quality in all aspects of their work.

These values are reflected in their patient support programs and their commitment to ethical business practices. For example, Amicus provides comprehensive support services to patients and families, ensuring access to their therapies and ongoing care.

Amicus Therapeutics' financial performance in 2024 further illustrates its commitment to growth and innovation. The company’s strategic focus on rare diseases, combined with its strong financial position, positions it as a key player in the biotechnology industry. To gain more insights into the investors of Amicus Therapeutics, Inc. (FOLD), check out this informative resource: Exploring Amicus Therapeutics, Inc. (FOLD) Investor Profile: Who’s Buying and Why?

Amicus Therapeutics, Inc. (FOLD) Core Values of

Amicus Therapeutics, Inc. is committed to a set of core values that guide its operations and interactions with patients, partners, and employees. These values reflect the company's dedication to innovation, collaboration, and making a meaningful difference in the lives of people living with rare diseases. The core values are integral to Amicus's mission and vision, shaping its culture and influencing its strategic decisions.

Focus on the Patient

Amicus Therapeutics places patients at the center of everything it does. This commitment is reflected in its efforts to develop and deliver innovative therapies that address unmet medical needs in the rare disease community. Amicus actively engages with patient advocacy groups to understand the challenges faced by patients and their families, ensuring that their voices are heard and incorporated into the company's decision-making processes.

Examples of Amicus's patient-focused approach include:

• Developing therapies that are convenient and easy for patients to administer.
• Providing patient support programs that offer education, resources, and assistance to patients and their families.
• Collaborating with patient advocacy groups to raise awareness of rare diseases and advocate for policies that support patients.

In 2024, Amicus continued its commitment to patient support by expanding its patient assistance programs, providing financial aid and resources to eligible patients to ensure access to its therapies. Breaking Down Amicus Therapeutics, Inc. (FOLD) Financial Health: Key Insights for Investors

Commitment to Innovation

Amicus Therapeutics is dedicated to advancing scientific knowledge and developing innovative therapies that have the potential to transform the lives of patients with rare diseases. The company invests heavily in research and development, exploring new technologies and approaches to address unmet medical needs. Amicus fosters a culture of innovation, encouraging its employees to think creatively and challenge conventional wisdom.

Examples of Amicus's commitment to innovation include:

• Developing a novel class of pharmacological chaperones that stabilize misfolded proteins, a common cause of rare genetic diseases.
• Investing in gene therapy research to develop potentially curative treatments for rare diseases.
• Utilizing advanced technologies, such as artificial intelligence and machine learning, to accelerate drug discovery and development.

In 2024, Amicus increased its R&D investment to $424.4 million, demonstrating its ongoing commitment to innovation. This investment supports the development of new therapies and technologies aimed at addressing unmet needs in the rare disease community.

Collaboration

Amicus Therapeutics recognizes that collaboration is essential for success in the complex and rapidly evolving biotechnology industry. The company actively seeks out partnerships with academic institutions, research organizations, and other companies to leverage expertise and resources, accelerate drug development, and expand its reach to patients in need. Amicus values transparency, open communication, and mutual respect in its collaborations.

Examples of Amicus's commitment to collaboration include:

• Partnering with academic institutions to conduct research on the underlying causes of rare diseases and identify potential therapeutic targets.
• Collaborating with other biotechnology companies to develop and commercialize new therapies.
• Working with regulatory agencies to streamline the drug approval process and ensure that patients have timely access to innovative treatments.

In 2024, Amicus continued to foster collaborations with patient advocacy groups, providing support and resources to help raise awareness of rare diseases and improve patient outcomes. For example, Amicus partnered with the Fabry Support & Information Group (FSIG) to launch a new educational initiative aimed at improving the diagnosis and management of Fabry disease.

Integrity

Amicus Therapeutics operates with the highest standards of integrity, ensuring that all its actions are ethical, transparent, and compliant with applicable laws and regulations. The company is committed to fostering a culture of trust, respect, and accountability among its employees, partners, and stakeholders. Amicus believes that integrity is essential for building long-term relationships and maintaining its reputation as a responsible corporate citizen.

Examples of Amicus's commitment to integrity include:

• Adhering to strict ethical guidelines in all its business practices.
• Maintaining transparency in its communications with patients, healthcare professionals, and investors.
• Promoting a culture of compliance and accountability throughout the organization.

In 2024, Amicus reinforced its commitment to ethical business practices by implementing enhanced compliance training programs for its employees. These programs cover topics such as anti-corruption, data privacy, and conflict of interest, ensuring that all employees understand and adhere to the company's ethical standards.

Accountability

Amicus Therapeutics holds itself accountable for its performance and strives to deliver on its commitments to patients, partners, and shareholders. The company sets ambitious goals, tracks its progress closely, and takes corrective action when necessary to ensure that it achieves its objectives. Amicus values transparency and open communication, providing regular updates on its progress and challenges.

Examples of Amicus's commitment to accountability include:

• Establishing clear metrics to measure the success of its research and development programs.
• Regularly reporting its financial performance and progress on key initiatives to investors.
• Seeking feedback from patients and healthcare professionals to improve its products and services.

In 2024, Amicus demonstrated its commitment to accountability by achieving several key milestones in its clinical development programs. The company reported positive results from its Phase 3 clinical trial of AT-GAA in patients with Pompe disease, paving the way for regulatory submissions in the United States and Europe. Total revenue for 2024 was reported at $526.4 million, an increase of 22.5% compared to 2023.